Literature DB >> 72289

Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen.

T W Meade, A P Haines, W R North, R Chakrabarti, D J Howarth, Y Stirling.   

Abstract

In 15 women on oral contraceptives containing 30 microgram oestrogen, mean values for factors II, VII, and X, fibrinogen, fibrinolytic activity, antithrombin III, cholesterol, and fasting triglycerides were intermediate between values for 63 women on preparations containing 50 microgram oestrogen and those for 243 premenopausal women not on oral contraceptives. Mean blood-pressure levels, however, were higher in women on 30 microgram than in those on 50 microgram preparations. In 28 women on 50 microgram preparations containing 3 mg or 4 mg norethisterone, mean values of factor VII, fibrinogen, fibrinolytic activity, cholesterol, fasting triglycerides, and systolic blood-pressure were higher than in 15 women whose preparations contained only 1 mg of norethisterone. A less consistent picture was found in women on 30 microgram oestrogen preparations containing either 250 microgram (10 women) or 150 microgram (5 women) d-norgestrel. It is concluded that 30 microgram oestrogen preparations probably result in smaller hemostatic and lipid changes than 50 microgram preparations but that they may have a blood-pressure-raising effect attributable to the particular progestagen, d-norgestrel, used in 30 microgram preparations. The safety of these 30 microgram oestrogen preparations may thus depend partly on the balance between these two sets of effects. It is also concluded that norethisterone may have effects similar to those attributed to oestrogens.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 72289     DOI: 10.1016/s0140-6736(77)90888-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  21 in total

1.  Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.

Authors:  T W Meade
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

2.  Distribution of high density and other lipoproteins in selected LRC prevalence study populations: a brief survey.

Authors:  B M Rifkind; I Tamir; G Heiss; R B Wallace; H A Tyroler
Journal:  Lipids       Date:  1979-01       Impact factor: 1.880

3.  Blood pressure and contraceptive use.

Authors:  K T Khaw; W S Peart
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-07

4.  ABC of blood pressure management.

Authors:  P Semple
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-20

5.  Successful pregnancy soon after oral contraceptive-associated malignant hypertension.

Authors:  J H Silas; H F Woods; A Singer; V A Brown
Journal:  Postgrad Med J       Date:  1980-11       Impact factor: 2.401

6.  The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients.

Authors:  T Fukutomi; T Nanasawa; H Yamamoto; I Adachi; T Watanabe
Journal:  Jpn J Surg       Date:  1990-11

Review 7.  Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies.

Authors:  Jane Morley Kotchen; Theodore A Kotchen
Journal:  Curr Hypertens Rep       Date:  2003-12       Impact factor: 5.369

8.  The effect of low-dose estroprogestinic preparations on prothrombin complex factors: no significant increase after an 8-month trial.

Authors:  A Girolami; M Procidano; M Vicariotto; G Cappellato; T Vicari
Journal:  Blut       Date:  1985-03

Review 9.  Hepatobiliary complications of oral contraceptives.

Authors:  M C Lindberg
Journal:  J Gen Intern Med       Date:  1992 Mar-Apr       Impact factor: 5.128

10.  Estrogen modulates ClC-2 chloride channel gene expression in rat kidney.

Authors:  Danielle S Nascimento; Carlos U Reis; Regina C Goldenberg; Tânia M Ortiga-Carvalho; Carmen C Pazos-Moura; Sandra E Guggino; William B Guggino; Marcelo M Morales
Journal:  Pflugers Arch       Date:  2003-06-17       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.